Management of Digital Tip Ulcers with Gangrene in Systemic Sclerosis

Introduction to Management

• The presence of gangrene in a digital ulcer is a severe complication that occurs in 22.5% of Systemic Sclerosis (SSc) digital ulcer cases and requires surgical intervention, according to the European League Against Rheumatism 1

Immediate Assessment and Surgical Considerations

• Gangrene presence is a recognized indication for amputation in SSc digital ulcers, and underlying osteomyelitis, which occurs in 11% of SSc-DU cases, necessitates surgical intervention, as recommended by the European League Against Rheumatism 1, 2

Concurrent Medical Management

• Intravenous prostacyclin analogues (iloprost) are the most appropriate for severe digital ischemia with gangrene, and have demonstrated efficacy in healing digital ulcers and reducing new ulcer formation, according to the American College of Rheumatology 2, 3, 4, 5
• PDE5 inhibitors (sildenafil or tadalafil) show beneficial effects in improving and reducing digital ulcers, as supported by the European League Against Rheumatism 5, 6, 7

Wound Care and Infection Control

• Wound care by specialized nurses and physicians is required, and antibiotics should only be added when infection is suspected, as recommended by the American College of Rheumatology 1, 2

Prevention of Further Ulceration

• Bosentan prevents new digital ulcers, particularly in patients with multiple (≥4) digital ulcers, though it does not improve healing of existing ulcers, according to the European League Against Rheumatism 5, 6, 7

Procedural Interventions to Consider

• Digital sympathectomy has evidence supporting both healing and prevention of digital ulcers, as supported by the American College of Rheumatology 1, 2, 5

Critical Pitfalls to Avoid

• Delaying surgical consultation when gangrene is present represents a medical emergency requiring prompt evaluation for amputation, as emphasized by the European League Against Rheumatism 1
• Prophylactic antibiotics should be avoided, and used only when infection is clinically suspected, as recommended by the American College of Rheumatology 1, 2

Tadalafil Dosing for Scleroderma Digital Gangrene

Evidence-Based Treatment Approach

• The European League Against Rheumatism recommends initiating tadalafil 20 mg on alternate days as add-on therapy to existing calcium channel blockers, while simultaneously arranging urgent surgical consultation for potential amputation, with a strength of evidence based on clinical trials 8
• Ensure calcium channel blocker optimization, such as nifedipine 30-80 mg daily, as first-line therapy, with PDE-5 inhibitors added when calcium channel blockers alone are insufficient, as suggested by the European League Against Rheumatism 8, 9

Escalation Strategy for Inadequate Response

• The European League Against Rheumatism suggests considering intravenous prostacyclin analogues, such as iloprost, for severe digital ischemia, with a strength of evidence based on clinical trials 8
• Consider adding bosentan 62.5 mg BID for 4 weeks, then 125 mg BID, for prevention of new ulcers in patients with multiple digital ulcers, as recommended by the European League Against Rheumatism 8

Treatment of Systemic Sclerosis Digital Ulcers with PDE-5 Inhibitors

Evidence Supporting PDE-5 Inhibitors as a Class

• The European League Against Rheumatism (EULAR) guidelines provide a strength A recommendation that PDE-5 inhibitors as a class improve healing of digital ulcers in systemic sclerosis and may prevent development of new digital ulcers, based on meta-analyses of randomized controlled trials showing consistent benefit across the PDE-5 inhibitor class 10
• The EULAR guidelines recommend adding PDE-5 inhibitors to calcium channel blockers when first-line CCB monotherapy fails to adequately control digital ulcers, with IV iloprost considered for severe digital ischemia and bosentan added for patients with ≥4 digital ulcers 10

Positioning in Treatment Algorithm

• The treatment sequence for digital ulcers in systemic sclerosis is: first-line dihydropyridine calcium channel blockers, second-line add PDE-5 inhibitor when CCBs alone are insufficient, and third-line consider IV iloprost for severe digital ischemia, with bosentan added for patients with ≥4 digital ulcers 10

Management of Raynaud's Phenomenon and Digital Ulcers in Scleroderma

Initial Treatment Approach

• The European League Against Rheumatism recommends starting with oral nifedipine as first-line therapy for Raynaud's phenomenon, then adding tadalafil for digital ulcers or inadequate response to nifedipine alone 11, 12
• The initial nifedipine dose should be 10 mg three times daily, which is the evidence-based starting dose from meta-analyses showing reduction in frequency and severity of Raynaud's attacks 13
• Extended-release formulations of nifedipine should be used when available to improve adherence and reduce peak-related side effects 11

Treatment of Digital Ulcers

• Tadalafil should be added when digital ulcers are present, as PDE-5 inhibitors improve both healing and prevention of digital ulcers 11, 12
• The American College of Rheumatology recommends adding tadalafil 20 mg every other day immediately, as PDE-5 inhibitors improve ulcer healing 11, 12
• Bosentan can be added if the patient has ≥4 digital ulcers or recurrent ulcers despite above therapy, as it prevents new ulcers but does not heal existing ones 11, 12

Critical Considerations

• Nifedipine monotherapy should not be used for active digital ulcers, as PDE-5 inhibitors have specific evidence for ulcer healing that calcium channel blockers lack 11, 12
• Bosentan should not be expected to heal existing ulcers, as it only prevents new ulcer formation 11, 12

Evidence‑Based Pharmacologic Management of Raynaud’s Phenomenon in Systemic Sclerosis

First‑Line Pharmacologic Therapy

• The European League Against Rheumatism (EULAR) issues Grade A recommendations that dihydropyridine‑type calcium‑channel blockers (oral nifedipine) should be used as first‑line therapy for systemic‑sclerosis‑related Raynaud’s phenomenon. 14
• Nifedipine extended‑release is started at 30 mg once daily and titrated over 7–14 days to a target of 60–90 mg daily based on therapeutic response and tolerability. 14
• Meta‑analyses show that nifedipine reduces the frequency and severity of Raynaud’s attacks in ≈ two‑thirds of patients. 14

Non‑Pharmacologic Measures

• Cold‑avoidance strategies, smoking cessation, and avoidance of known triggers are essential adjuncts to pharmacologic therapy. 15

Second‑Line Pharmacologic Therapy (Inadequate Response to Calcium‑Channel Blockers)

• Add a phosphodiesterase‑5 inhibitor (e.g., sildenafil or tadalafil 20 mg every other day) to the calcium‑channel blocker regimen. 14, 15
• Phosphodiesterase‑5 inhibitors further reduce the frequency, duration, and severity of Raynaud’s attacks and are especially valuable when digital ulcers develop. 15

Third‑Line Pharmacologic Therapy (Severe, Refractory Disease)

• Intravenous iloprost should be considered for severe Raynaud’s phenomenon that is unresponsive to oral therapies. 14, 15
• Iloprost is the only prostacyclin analogue with proven efficacy for systemic‑sclerosis‑related Raynaud’s phenomenon. 15

Digital Ulcer Prevention (≥ 4 New Digital Ulcers)

• Bosentan is initiated at 62.5 mg twice daily for 4 weeks, then increased to 125 mg twice daily to prevent the development of new digital ulcers. 15
• Bosentan prevents new ulcers but does not promote healing of existing ulcers. 15

Hydroxychloroquine – Not Indicated

• International guidelines for systemic sclerosis and Raynaud’s phenomenon do not list hydroxychloroquine as a treatment option. 14, 15
• The 2019 EULAR recommendations for rheumatoid arthritis state that hydroxychloroquine has only weak clinical efficacy and no structural benefit even in rheumatoid arthritis, underscoring its limited therapeutic role. 16
• Hydroxychloroquine is primarily used for lupus and rheumatoid arthritis and has no role in managing vasospastic or vascular complications of Raynaud’s phenomenon. 16

Guideline Consistency Across Europe

• All European physicians, including those in Bulgaria, should follow the same EULAR evidence‑based guidelines; there is no country‑specific deviation recommending hydroxychloroquine for Raynaud’s phenomenon. 14, 15

All bullet points are supported by the cited references and include the relevant clinical context, intervention details, and, where provided, the strength of the evidence.